Skip to main content
main-content

Free registration

Medicine Matters is developed for healthcare professionals as

a premier resource for the latest clinical information in medicine.

Editor's pick

15-03-2019 | Non-small cell lung cancer | News

Risk for severe irAEs noted with sequential PD-1/PD-L1 blockade and osimertinib

Patients with advanced EGFR mutation-positive non-small-cell lung cancer who receive osimertinib directly after agents targeting PD-1 or PD-L1 may be at increased risk for developing severe immune-related adverse events, suggests a chart review.

Updates in sarcoma from ASCO and ESMO 2018

Presented by Jean-Yves Blay (Leon Berard Center, Lyon, France)

This downloadable slide collection, based on a webinar presented by World Sarcoma Network Chairman Professor Jean-Yves Blay, highlights and summarizes key recent findings in sarcoma presented at the 2018 ASCO Annual Meeting and the 2018 ESMO Congress.

This educational initiative was funded by Eli Lilly and Company.

28-02-2019 | Lung cancer | At a glance | Article

At a glance: CheckMate lung cancer trials

Here we round up the CheckMate trials evaluating the PD-1 inhibitor nivolumab in non-small-cell lung cancer and small-cell lung cancer.

Specialty

Latest from across the site

19-03-2019 | Castration-resistant prostate cancer | News

AR-V7 status predicts abiraterone, enzalutamide response in mCRPC

Men positive for androgen receptor splice variant 7 in circulating tumor cells derive little benefit from abiraterone or enzalutamide in the treatment of metastatic castration-resistant prostate cancer, US researchers report.

18-03-2019 | Risk factors | News

Infertility linked to increased risk for multiple cancer types

Women with infertility have a significantly higher risk than those without for both hormonal and nonhormonal cancers, but the absolute risk in both groups is low, shows an analysis of US insurance claims data.

15-03-2019 | Non-small cell lung cancer | News

Risk for severe irAEs noted with sequential PD-1/PD-L1 blockade and osimertinib

Patients with advanced EGFR mutation-positive non-small-cell lung cancer who receive osimertinib directly after agents targeting PD-1 or PD-L1 may be at increased risk for developing severe immune-related adverse events, suggests a chart review.

14-03-2019 | Aspirin | News

Aspirin does not improve prostate cancer-specific survival, but may reduce lung cancer incidence

A Danish study has found no protective effect of low-dose aspirin taken after diagnosis on prostate cancer-specific mortality, while South Korean research has identified a link between long-term use of the nonsteroidal anti-inflammatory drug and a reduced risk for incident lung cancer.

13-03-2019 | Castration-resistant prostate cancer | News

Phase III data show no support for PROSTVAC in mCRPC

A phase III trial investigating the efficacy of PROSTVAC, a viral vector–based immunotherapy, in the treatment of metastatic castration-resistant prostate cancer was stopped early due to a lack of positive results, say researchers.

12-03-2019 | Prostate cancer | News

Intense neoadjuvant ADT explored in locally advanced prostate cancer

Intense androgen deprivation therapy before radical prostatectomy benefits some patients with locally advanced prostate cancer, report researchers who found that results may be better with a four-drug than a two-drug regimen.

Steering improved outcomes in non-driver mutation lung cancer: Progress and challenges

Steering improved outcomes in lung cancer

This program was made possible thanks to an independent educational grant from Eli Lilly and Company. Produced by Springer Healthcare Independent Medical Education.

Gastric cancer care: From evidence to practice

Gastric cancer care

This program was made possible thanks to independent educational sponsorship from Eli Lilly and Company. Produced by Springer Healthcare Independent Medical Education.

Scientific summary

Diffuse large B-cell lymphoma management: Exploring novel treatment strategies

Diffuse large B-cell lymphoma management: Exploring novel treatment strategies

This program was made possible thanks to independent educational sponsorship from MorphoSys.

Soft tissue sarcoma: What is best practice?

 Soft tissue sarcoma: What is best practice?

This program was made possible thanks to independent educational sponsorship from Eli Lilly and Company. Produced by Springer Healthcare Independent Medical Education.

Meet the Editorial Board


Our international Editorial Board members Dr Fiona Blackhall (Christie Hospital, Manchester, UK) and Dr Axel Merseburger (University Hospital Schleswig-Holstein, Germany) work closely with the editorial team to highlight gaps in coverage and select topics to feature on this digital platform.

Why register? Medicine Matters oncology is a free resource providing the latest news and clinical guidance

Register today and receive updates directly to your inbox!
Medicine Matters oncology has been specifically developed for the time-limited healthcare professional who is looking for a single resource providing credible information on current practice and the latest advances in oncology.
Already registered? Log in now to unlock your access.

Latest from us on Twitter

Updates from oncology organizations

New Content Item Meet our Advisory Board

image credits